Zübeyde Nur ÖZKURT, Ramazan ÖCAL, Mehmet Sezgin PEPELER, Burcu ÜLKÜDEN

Meme Kanserli bir Hastada Capecitabin İlişkili ve t(10;11) (q22;q23) Pozitif Akut Myeloblastik Lösemi

Capesitabin tek başına veya kombinasyon tedavileri ile kullanılabilen ve oral yolla kullanılan bir tedavi ajanıdır. Capesitabin kullanımı ile ilişkilendirilen tedavi ilişkili lösemi olguları oldukça nadirdir. Biz 39 yaşında metastatic meme kanserli bir olguyu sunduk. Hasta Capesitabin ile tedavi edildikten sonra akut myelomonositik lösemi ile başvurdu. t(10;11)(q22;q23) konvansiyonel sitogenetik çalışmada saptandı. İndüksiyon kemoterapi ile remisyon sağlanmasına karşın daha sonra relaps gelişti. Kurtarma kemoterapi verildi, ancak hasta kaybedildi. Bu vaka Capesitabin kullanımı sonrası t(10;11)(q22;q23) ile birlikte t-AML geliştiğini gösteren ilk rapordur. T-AML gelişimi yüksek hastalar Capesitabin kullanımı sırasında yakından izlenmelidir.

Capecitabine Induced Therapy Related Acute Myeloblastic Leukemia with t(10;11) (q22;q23) in a Patient with Breast Cancer

Capecitabine is an oral agent that is used either as single agent or incombination therapy. Therapy related acute myeloblastic leukemia aftercapecitabine use is rarely reported. We presented a 39-year-old woman withmetastatic breast cancer. She admitted with acute myelomonocytic leukemiaafter treating with oral Capecitabine. t(10;11)(q22;q23) was determined inconventional cytogenetic analysis. She achieved complete remission withintensive chemotherapy but relapse developed. She died although the salvagechemotherapy. To our knowledge our patients is the first report with t-AMLwith t(10;11)(q22;q23) secondary to Capecitabine use for breast cancertreatment. Capecitabine should be carefully used especially in patients withhigh risk for t-AML.

PDF

___

Godley LA, Larson RA. Therapy-related myeloid leukemia. Semin Oncol 2008; 35: 418-29
Walko CM, Lindley C. Capecitabine: A Review. Clin Ther 2005; 27:23-44
Shapiro S, Hughes G, Al-Obaidi MJ, et al. Acute myeloid leukemia secondary to treatment with capecitabine for metastatic colorectal cancer. Eur J Hematol 2007; 78:543-4
Rashidi A, Man L, Howard JR, et al. Therapy-related acute promyelocytic leukemia after chemoradiotherapy with capecitabine for rectal adenocarcinoma. Leuk Lymphoma 2014; 55: 683-4
Tansley S, Gibbons S. Capecitabine-induced acute myeloid leukaemia. N Z Med J 2009;122:118-28
Zhang YC, Zhou YO, Yan B, et al. Secondary acute promyelocytic leukemia following chemotherapy for gastric cancer: A case report. World J Gastroenterol 2015; 21: 4402-7
Damodaran S, Bellavia T, Sait SNJ, et al. Acute myeloid leukemia secondary to Oxaliplatin treatment for esophageal cancer. Clin Colorectal Cancer 2012; 11: 151-4
Bueso-Ramos CE, Kanagal-Shamanna R, Routbort MJ, et al. Therapy-Related Myeloid Neoplasm. Am J Clin Pathol. 2015;144:207-18
Ono R, Taki T, Taketani T, et al. LCX, leukemia-assciated protein with a CXX domain, is fused to MLL in acute myeloid leukemia with trilinage dysplasia. Cancer Research 2002; 62:4075-80
Lorsbach RB, Moore J, Mathew S, et al. TET1, a member of a novel protein family, is fused to MLL in acutevmyeloid leukemia containing the t(10;11)(q22;q23). Leukemia 2003; 17:637-41
Pigneux A, Labopin M, Maertens J, et al. On Behalf of the Acute Leukemia Working Party EBMT. Outcome of allogeneic hematopietic ste cell transplantation for adult patients with AML and 11q23/MLL rearrangement (MLL-rAML) Leukemia 2015; 29: 2375-81
DiNardo CD, Tang G, Pemmaraju N, et al. Acute myeloid leukemia with t(10;11): a pathological entity with distinc clinical presentation. Clin Lymhoma Myeloma Leuk 2016; 15:47-51
Wolff AC, Blackford AL, Visvanathan K, et al. Risk of Marrow Neoplasms After Adjuvant Breast Cancer Therapy: The National Comprehensive Cancer Network Experience J Clin Oncol 2015; 33: 340–8
Armand P, Kim HT, Mayer E, et al. Outcome of allo-SCT for women with MDS or AML occurring after breast cancer therapy Bone Marrow Transplant 2010; 45: 1611–7